System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Multicenter Study Observational Study Ppublish

PubMed: 42701883 DOI: 10.1002/clc.70466

Prospective Evaluation of Quality-of-Life Improvement After Dapagliflozin Initiation in a Greek Population With HFrEF: The EVOLUTION-HF 12-Month Results.

Clin Cardiol 49(9):e70466

Authors: Victoria Potoupni, Aristi Boulmpou, Spyridon Maragkoudakis, Alexandros Briasoulis, Emmanouil Foukarakis, Alexia Stavrati, Konstantinos Papadopoulos, Katerina K Naka, Anna Kotsia, Ioannis Parissis, Antonios Ziakas, Stamatis Adamopoulos, Dimitrios Tziakas, Sotirios Patsilinakos, Melanie Konstantinidou, Periklis Davlouros, Zacharias Christogiannis, Konstantinos Tsitlakidis, Ioannis Pantelakis, Georgios Stefanakis, Marios Kolios, Ioannis Baltogiannis, Evangelos Voltyrakis, Christos Varounis, Andreas Samothrakitis, Dimitrios Krikidis, Panagiotis Tsialoukis, Zoe Paparepa, Dimitrios Gourlis, Nikolaos Papoutsidakis, Apostolos Karavidas, Christodoulos Papadopoulos

Affiliations

  • Third Cardiology Department, Hippokrateion General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Department of Cardiology, Chania General Hospital 'Agios Georgios', Chania, Greece.
  • Department of Clinical Therapeutics, Alexandra Hospital, Faculty of Medicine, National and Kapodistrian University of Athens, Psachna, Greece.
  • Department of Cardiology, Venizeleion General Hospital, Heraklion, Greece.
  • Department of Cardiology, General Hospital G. Papanikolaou, Thessaloniki, Greece.
  • 2nd Cardiology Department, "Korgialenio-Benakio" Red Cross Hospital, Athens, Greece.
  • 2nd Department of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, and University Hospital of Ioannina, Ioannina, Greece.
  • Department of Cardiology, Ioannina State General Hospital "G. Chatzikosta", Ioannina, Greece.
  • Emergency Medicine Department, Attikon University Hospital, National and Kapodistrian University of Athens, Athina, Greece.
  • Department of Cardiology, AHEPA General University Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Heart Failure, Transplant and Mechanical Circulatory Support Units, Onassis Cardiac Surgery Center, Athens, Greece.
  • Department of Cardiology, University Hospital of Alexandroupolis, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
  • Department of Cardiology, Konstantopouleio General Hospital, Athens, Greece.
  • Department of Cardiology, Papageorgiou Hospital, Thessaloniki, Greece.
  • Department of Cardiology, Faculty of Medicine, School of Health Sciences, University Hospital of Patras, Rio, Greece.
  • Cardiologist, Private Practice, Greece.
  • 2nd Cardiology Department, Hippokrateion General Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • AstraZeneca Greece, Marousi, Greece.
  • Department of Cardiology, "G. Gennimatas" General Hospital, Athens, Greece.

Abstract

INTRODUCTION

Heart failure with reduced ejection fraction (HFrEF), defined by a left ventricular ejection fraction ≤ 40%, remains a major global health challenge, associated with substantial morbidity, mortality, and impaired quality of life (QoL), particularly in patients with higher NYHA class. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a cornerstone therapy for HFrEF, significantly reducing hospitalizations and mortality regardless of glycemic status, sex, race, or comorbidities.

METHODS

EVOLUTION-HF was an observational, multi-center, longitudinal cohort study involving 257 consecutive patients diagnosed with HFrEF who initiated dapagliflozin in a routine clinical setting in Greece. The primary objectives were to characterize baseline demographic and clinical features of patients newly initiated on dapagliflozin for HFrEF and to evaluate dapagliflozin treatment patterns, including discontinuation timing, reasons for discontinuation, and concomitant heart failure and glucose-lowering therapies over time. The secondary objectives are to describe patient-reported outcomes using the KCCQ-23 and to assess adherence to dapagliflozin among patients with HFrEF.

RESULTS

A total of 257 patients were enrolled and the follow-up period lasted for 12 months. Significant improvements among all KCCQ-23 scores were observed from baseline to 12-months post dapagliflozin initiation, revealing that the initiation and optimization of guideline-directed medical therapy in routine clinical practice provides improvement to quality of life over time.

CONCLUSIONS

Dapagliflozin was safe and well-tolerated throughout the observation period. Although benefits are observed in most patients, individuals aged > 65 years, with prior myocardial infarction, or recent hospitalizations show a diminished response, underscoring the need for tailored management and closer follow-up in these higher-risk groups.

MeSH

Diabetes Mellitus, Quality Of Life, Mortality, Hospitalization, Heart Failure, Cardiology, Heart Failure, Systolic, Therapeutics